Metformin in Prostate Cancer: A Negative Repurposing Story Across the Disease Continuum [0.03%]
二甲双胍在前列腺癌中的再利用研究：贯穿疾病全程的负面故事
Dries Develtere,Gaëtan Devos
Dries Develtere
Single Port Robotic Radical Prostatectomy: A Propensity-matched Comparison of Transvesical Versus Extraperitoneal Approaches from the Single Port Advanced Research Consortium [0.03%]
经膀胱途径与腹膜外途径单孔机器人根治性前列腺切除术的倾向匹配分析
Nicolas A Soputro,Jacob Hershenhouse,Sam Cole et al.
Nicolas A Soputro et al.
Background and objectives: Single Port (SP) robotic radical prostatectomy (RARP) has been increasingly used, with Extraperitoneal (EP) and Transvesical (TV) approaches being the most common. This study sought to describe ...
PI-RADS v2 and Adverse Prostate Cancer Outcomes: A Cross-cohort Replication Study Across Three Centers [0.03%]
PI-RADS v2与前列腺癌不良预后：三大中心队列的验证研究
Tolou Shadbahr,Juho Pylväläinen,Juho Eineluoto et al.
Tolou Shadbahr et al.
Background and objective: Magnetic resonance imaging (MRI) coupled with Prostate Imaging-Reporting and Data System (PI-RADS) provides standardization for assessing the clinical significance of prostate cancer (PCa). The a...
Toward Improved Kidney Cancer Risk Prediction Using High-risk Genetic Variants and Polygenic Risk Scores [0.03%]
基于高风险遗传变异和多基因风险评分改善肾癌风险预测
James Whitworth
James Whitworth
Pembrolizumab Plus Lenvatinib in Participants with Docetaxel-pretreated Metastatic Castration-resistant Prostate Cancer: Results from KEYNOTE-365 Cohort E [0.03%]
派姆单抗联合乐伐替尼治疗多西他赛经治的转移性去势抵抗性前列腺癌受试者：Ⅱb 期 KEYNOTE-365 研究队列 E 结果
Marinela Augustin,Brigitte Laguerre,Capucine Baldini et al.
Marinela Augustin et al.
Pembrolizumab has shown manageable safety and modest antitumor activity when used as a single agent in participants with metastatic castration-resistant prostate cancer (mCRPC). Preclinical evidence suggests that lenvatinib, a vascular endo...
SBRT for High-risk Localised Prostate Cancer: SHARP and the Limits of Non-randomised Evidence [0.03%]
高危局限性前列腺癌的立体定向放射治疗：SHARP研究及其非随机对照证据的局限性
Peter J Hoskin,Ananya Choudhury
Peter J Hoskin
Beyond Clear Cell: Rethinking Postoperative Surveillance for Non-clear Cell Renal Cell Carcinoma Subtypes [0.03%]
超越透明细胞：重新思考非透明细胞肾细胞癌亚型术后监测方法
Arighno Das,Elizabeth E Ellis,Pheroze Tamboli et al.
Arighno Das et al.
Background and objective: Current risk stratification for non-clear cell renal cell carcinoma (nccRCC) is largely derived from clear cell RCC (ccRCC) data. We evaluated recurrence patterns following surgery for nccRCC and...
Salvage High-intensity Focused Ultrasound for Prostate Cancer Recurrence after Radiotherapy (HIFI-2 Study) [0.03%]
高密度超声聚焦治疗放射治疗后前列腺癌复发（HIFI-2研究）
Guillaume Ploussard,Patrick Coloby,Thierry Chevallier et al.
Guillaume Ploussard et al.
Background and objective: Management of local prostate cancer (PCa) recurrence after primary radiotherapy (RT) remains challenging in daily practice. Salvage high-intensity focused ultrasound (S-HIFU) represents a valid o...
When Patients Refuse Radical Cystectomy: Integrating Trimodality Therapy in the Perioperative ICI/ADC Era [0.03%]
当患者拒绝根治性膀胱切除术时：ICI/ADC时代的围手术期三联疗法整合治疗
Martino Pedrani,Alberto De Giorgi,Andrea Gallina et al.
Martino Pedrani et al.
Reply to A. Light, H. Ahmed H, T. Shah's Letter to the Editor re: M. Baboudjian, A. Uleri, J. Anract, et al. Targeted, Perilesional, and Distant Biopsies in Prostate Cancer Eur Urol Oncol. In press. http://dx.doi.org/10.1016/j.euo.2026.02.006 [0.03%]
关于A.Light，H.Ahmed H，T.Shah的来信：对M.Baboudjian，A.Uleri，J.Anract等人的评论回复前列腺癌的靶区、瘤周和远处活检《EurUrolOncol》待刊http://dx.doi.org/10.1016/j.euo.2026.02.006
Alessandro Uleri,Romain Diamand,Guillaume Ploussard et al.
Alessandro Uleri et al.